Yarrow Bioscience Inc (YARW) - Net Assets
Based on the latest financial reports, Yarrow Bioscience Inc (YARW) has net assets worth $24.64 Million USD as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($25.87 Million) and total liabilities ($1.24 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore YARW net assets growth trend to track the company's year-over-year net asset growth rate.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $24.64 Million |
| % of Total Assets | 95.22% |
| Annual Growth Rate | N/A |
| 5-Year Change | -42.91% |
| 10-Year Change | N/A |
| Growth Volatility | 79.6 |
Yarrow Bioscience Inc - Net Assets Trend (2015–2025)
This chart illustrates how Yarrow Bioscience Inc's net assets have evolved over time, based on quarterly financial data. See how leveraged is Yarrow Bioscience Inc's balance sheet to measure how much of total assets are equity-financed.
Annual Net Assets for Yarrow Bioscience Inc (2015–2025)
The table below shows the annual net assets of Yarrow Bioscience Inc from 2015 to 2025. For live market cap and overall valuation, see Yarrow Bioscience Inc market cap and net worth.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $27.77 Million | -46.69% |
| 2024-12-31 | $52.09 Million | -41.30% |
| 2023-12-31 | $88.73 Million | +184.39% |
| 2022-12-31 | $31.20 Million | -35.85% |
| 2021-12-31 | $48.64 Million | +29.72% |
| 2020-12-31 | $37.49 Million | -45.27% |
| 2019-12-31 | $68.51 Million | -47.45% |
| 2018-12-31 | $130.38 Million | +328.60% |
| 2017-12-31 | $-57.03 Million | -93.72% |
| 2016-12-31 | $-29.44 Million | -84.55% |
| 2015-12-31 | $-15.95 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Yarrow Bioscience Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 74160600000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $3.00K | 0.01% |
| Other Comprehensive Income | $2.00K | 0.01% |
| Other Components | $785.41 Million | 2828.79% |
| Total Equity | $27.77 Million | 100.00% |
Yarrow Bioscience Inc Competitors by Market Cap
The table below lists competitors of Yarrow Bioscience Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Platform Turizm Tasimacilik AS
IS:PLTUR
|
$110.62 Million |
|
QRF SCA
BR:QRF
|
$110.62 Million |
|
Caravel Minerals Ltd
AU:CVV
|
$110.70 Million |
|
Noroo Paint
KO:090350
|
$110.73 Million |
|
Softstar Entertainment
TWO:6111
|
$110.57 Million |
|
Grange Resources Ltd
AU:GRR
|
$110.55 Million |
|
Bokusgruppen AB
ST:BOKUS
|
$110.55 Million |
|
Intema Insaat ve Tesisat Malzemeleri Yatirim ve Pazarlama AS
IS:INTEM
|
$110.53 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Yarrow Bioscience Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 52,086,000 to 27,765,000, a change of -24,321,000 (-46.7%).
- Net loss of 26,483,000 reduced equity.
- Other comprehensive income decreased equity by 18,000.
- Other factors increased equity by 2,180,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-26.48 Million | -95.38% |
| Other Comprehensive Income | $-18.00K | -0.06% |
| Other Changes | $2.18 Million | +7.85% |
| Total Change | $- | -46.69% |
Book Value vs Market Value Analysis
This analysis compares Yarrow Bioscience Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.03x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2015-12-31 | $-249265.63 | $41.52 | x |
| 2016-12-31 | $-243314.05 | $41.52 | x |
| 2017-12-31 | $-500298.25 | $41.52 | x |
| 2018-12-31 | $1086475.00 | $41.52 | x |
| 2019-12-31 | $362476.19 | $41.52 | x |
| 2020-12-31 | $52073.61 | $41.52 | x |
| 2021-12-31 | $42513.99 | $41.52 | x |
| 2022-12-31 | $24491.37 | $41.52 | x |
| 2023-12-31 | $21595.28 | $41.52 | x |
| 2024-12-31 | $3057.41 | $41.52 | x |
| 2025-12-31 | $1623.02 | $41.52 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Yarrow Bioscience Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -95.38%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -4646.14%
- • Asset Turnover: 0.02x
- • Equity Multiplier: 1.09x
- Recent ROE (-95.38%) is above the historical average (-113.91%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2015 | 0.00% | 0.00% | 0.00x | 0.00x | $-3.01 Million |
| 2016 | 0.00% | -2087.24% | 0.02x | 0.00x | $-11.12 Million |
| 2017 | 0.00% | -634.57% | 0.07x | 0.00x | $-23.37 Million |
| 2018 | -39.46% | -483.51% | 0.08x | 1.07x | $-64.48 Million |
| 2019 | -102.86% | -15906.09% | 0.01x | 1.16x | $-77.31 Million |
| 2020 | -681.64% | -1217.40% | 0.22x | 2.50x | $-259.32 Million |
| 2021 | -150.77% | -7876.37% | 0.01x | 1.38x | $-78.19 Million |
| 2022 | -74.39% | -4865.83% | 0.01x | 1.31x | $-26.33 Million |
| 2023 | -32.06% | -6710.38% | 0.00x | 1.10x | $-37.33 Million |
| 2024 | -76.48% | -7950.90% | 0.01x | 1.28x | $-45.04 Million |
| 2025 | -95.38% | -4646.14% | 0.02x | 1.09x | $-29.26 Million |
Industry Comparison
This section compares Yarrow Bioscience Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $128,448,094
- Average return on equity (ROE) among peers: -37.92%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Yarrow Bioscience Inc (YARW) | $24.64 Million | 0.00% | 0.05x | $110.61 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-54.64 Million | 0.00% | 0.00x | $133.80 Million |
| Abcellera Biologics Inc (ABCL) | $1.15 Billion | -12.70% | 0.29x | $2.99 Billion |
| Abeona Therapeutics Inc (ABEO) | $-5.83 Million | 0.00% | 0.00x | $335.61 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $-11.42 Million | 0.00% | 0.00x | $155.29 Million |
| Abpro Holdings, Inc. (ABP) | $-75.73 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $179.13 Million | -57.56% | 0.19x | $1.50 Billion |
| Arbutus Biopharma Corp (ABUS) | $-10.50 Million | 0.00% | 0.00x | $906.70 Million |
| ABVC Biopharma Inc (ABVC) | $10.00K | -200.00% | 3.00x | $22.52 Million |
| Abivax SA American Depositary Shares (ABVX) | $71.77 Million | -22.23% | 0.06x | $10.37 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $39.37 Million | -86.70% | 0.59x | $5.07 Billion |
About Yarrow Bioscience Inc
Yarrow Bioscience, Inc. operates as a clinical-stage biotechnology company that engages in developing transformative therapies for autoimmune thyroid diseases. The company's candidate, YB-101, is a humanized monoclonal antibody targeting the thyroid-stimulating hormone receptor (TSHR) for the treatment of Graves' disease and thyroid eye disease. The company was incorporated in 2025 and is based i… Read more